68 related articles for article (PubMed ID: 10619454)
1. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Bland KI; Buzdar AU
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):12S-13S. PubMed ID: 10619454
[No Abstract] [Full Text] [Related]
2. Future directions in endocrine treatment of advanced breast cancer.
Bland KI
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):14S-16S. PubMed ID: 10619455
[No Abstract] [Full Text] [Related]
3. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
5. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
6. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Köberle D; Thürlimann B
Expert Rev Anticancer Ther; 2001 Aug; 1(2):169-76. PubMed ID: 12113022
[TBL] [Abstract][Full Text] [Related]
9. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
[TBL] [Abstract][Full Text] [Related]
10. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
11. Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Prescrire Int; 2001 Jun; 10(53):76-7. PubMed ID: 11718168
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid prevents cancer treatment-induced bone loss.
Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
[No Abstract] [Full Text] [Related]
13. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
14. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
15. Excessive sweating: unusual side effect of megestrol acetate therapy.
Votaw ML
Tenn Med; 1997 Feb; 90(2):59. PubMed ID: 9029997
[No Abstract] [Full Text] [Related]
16. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer.
Milla-Santos A; Milla L; Calvo N; Portella J; Rallo L; Casanovas JM; Pons M; Rodes J
Anticancer Res; 2004; 24(2C):1315-8. PubMed ID: 15154667
[TBL] [Abstract][Full Text] [Related]
17. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
18. Letrozole or tamoxifen in early breast cancer.
Chlebowski RT
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602149
[No Abstract] [Full Text] [Related]
19. Breast cancer drug shows promise for some survivors.
Levenson D
Rep Med Guidel Outcomes Res; 2003 Oct; 14(21):7-9. PubMed ID: 14628765
[No Abstract] [Full Text] [Related]
20. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Lavrenkov K; Man S; Geffen DB; Cohen Y
Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
